Effect of Pre-existing Adjacent Segment Degeneration on Long-term Effectiveness After Lumbar Fusion Surgery
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Jul 8, 2020
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how existing problems in the spine, such as degeneration of the discs and other structures near the spine, affect the long-term success of lumbar fusion surgery. This type of surgery is often recommended for patients with conditions like degenerative lumbar spinal stenosis (narrowing of the spinal canal) and degenerative disc disease, especially when non-surgical treatments haven't worked after at least eight weeks. By looking closely at the condition of the adjacent spinal segments before surgery, the researchers hope to understand how these factors could influence recovery and overall outcomes after the procedure.
To be eligible for this trial, participants must have a clear diagnosis of lumbar spinal stenosis and need to undergo surgery at the L4-S1 levels of the spine. However, those with certain conditions, such as spinal instability or previous lumbar surgery, won't be able to participate. If you decide to join the study, you'll be monitored closely after your surgery to track your progress and help researchers learn more about how pre-existing degeneration impacts recovery. This information could ultimately improve surgical outcomes for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A clear diagnosis of lumbar spinal stenosis, and surgical level of L4- S1 (The levels to be operated on were decided by matching the clinical symptomatology with the radiological findings of the spinal levels that needed decompression);
- • Failed at least eight weeks conservative treatment;
- Exclusion Criteria:
- • Unstable factors (slip, rotation, lateral bending, etc.) in adjacent segment L3/4;
- • Preoperative sagittal and coronal imbalance of the spine;
- • Lumbar infection and/or tumor diseases;
- • A previous history of lumbar fusion surgery.
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Beijing, Beijing, China
Patients applied
Trial Officials
Wei Shi Li, Dr.
Principal Investigator
Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials